<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365456</url>
  </required_header>
  <id_info>
    <org_study_id>FP-001-IM</org_study_id>
    <secondary_id>2005-000730-20</secondary_id>
    <secondary_id>U1111-1132-3246</secondary_id>
    <nct_id>NCT00365456</nct_id>
  </id_info>
  <brief_title>Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)</brief_title>
  <acronym>PEAK</acronym>
  <official_title>An Open Label, International, Multi Centre, Parallel Group, Phase III b, Randomised Trial, Investigating Lumbar Spine Bone Mineral Density (BMD) Changes in Postmenopausal Women With Primary Osteoporosis Initially Treated With 12 Months of Full Length Parathyroid Hormone (PTH 1-84) Followed by 12 Months of Treatment With Risedronate Followed by Either 12 Months Treatment With PTH (1-84) or Risedronate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to show superior efficacy of PTH (1-84) over risedronate in treating
      osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12
      months followed by 12 months treatment with risedronate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.</measure>
    <time_frame>12 months</time_frame>
    <description>BMD was measured by Dual X-ray Absorptiometry (DXA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>PTH (1-84)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid Hormone (PTH)</intervention_name>
    <description>Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.</description>
    <arm_group_label>PTH (1-84)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>Orally once weekly as one 35 mg tablet.</description>
    <arm_group_label>Risedronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women above the age of 50 years with the diagnosis of postmenopausal primary osteoporosis
        may be enrolled in the trial if the following inclusion/exclusion criteria apply.

        All inclusion criteria must be answered &quot;yes&quot; for a subject to be enrolled in the trial.

          1. Has the subject given informed consent according to local requirements before any
             trial related activities? (A trial related activity is any procedure that would not
             have been performed during the routine management of the subject).

          2. Is the subject above 50 years old?

          3. Is the subject postmenopausal (more than 5 years) - in the judgement of the
             investigator?

          4. Does the subject have primary osteoporosis with a lumbar spine T score &lt; -3.0 SD (at
             lumbar spine L1-L4, with a minimum of two evaluable vertebrae)?

          5. Does the subject have a life expectancy of &gt;3 years?

          6. Is the subject able to self-inject PTH (1-84), (or to have PTH (1-84) injection by a
             helper)?
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nycomed Clinical Trial Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Headquaters</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <results_first_submitted>May 4, 2012</results_first_submitted>
  <results_first_submitted_qc>June 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2012</results_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lumbar Spine Bone Mineral Density (BMD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was divided into 3 consecutive open-label treatment phases of 12 months with randomisation after Trial Period II.
From 407 enrolled patients in total, 2 patients were enrolled but were never exposed to trial treatment. Thus, 405 patients in total received trial treatment.</recruitment_details>
      <pre_assignment_details>Period I: total number of 405 patients were included and all received PTH(1-84) treatment for 1 year
Period II: of those 405 patients, 282 continued into the 2. year and all received risedronate
Period III: during the 3. year, the remaining 268 patients were randomised to either PTH(1-84) (=136 patients) or risedronate (=132 patients)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PTH (1-84)</title>
        </group>
        <group group_id="P2">
          <title>Risedronate</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Trial Period I (12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Trial Period II (12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Trial Period III (12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PTH(1-84) or Risedronate</title>
          <description>PTH(1-84) received by 405 participants in Trial Period I
of those 405 participants, 282 received Risedronate in Trial Period II
of those 282 participants, 268 participant remained and 136 received PTH(1-84) and 132 received Risedronate in Trial Period III</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar spine T-score</title>
          <description>The T-score represents the lumbar spine bone mineral density as compared to a young normal reference mean (healthy 30-year-old woman). A score ≥ -1.0 is considered Normal, while a score between -1.0 and -2.5 is defined as Osteopenia and a score ≤ -2.5 is defined as Osteoporosis.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.61" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.62" spread="0.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.60" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.63" spread="0.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prevalent vertebral fractures</title>
          <description>Number of patients with at least one vertebral fracture at baseline</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prevalent non-vertebral fragility fractures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84): hip fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate: hip fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84): hip fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate: hip fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period I / PTH(1-84): wrist fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate: wrist fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84): wrist fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate: wrist fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period I / PTH(1-84): others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate: others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84): others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate: others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.4" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.5" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.6" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.4" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Calcium</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.338" spread="0.1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.337" spread="0.0999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.337" spread="0.0961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.339" spread="0.1041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Trial Period I / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.06" spread="3.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period II / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.11" spread="3.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / PTH(1-84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.06" spread="3.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Period III / Risedronate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.21" spread="3.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.</title>
        <description>BMD was measured by Dual X-ray Absorptiometry (DXA).</description>
        <time_frame>12 months</time_frame>
        <population>All randomized patients made the Full Analysis Set which was used for the primary and secondary analyses according to intention-to-treat principles. One participant excluded due to missing baseline data at trial period III entry, thus no data could be carried forward for this patient. Missing values imputed by Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>PTH (1-84)</title>
            <description>Regimen 1 = PTH (1-84) → Risedronate → PTH (1-84)</description>
          </group>
          <group group_id="O2">
            <title>Risedronate</title>
            <description>Regimen 2 = PTH (1-84) → Risedronate → Risedronate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.</title>
          <description>BMD was measured by Dual X-ray Absorptiometry (DXA).</description>
          <population>All randomized patients made the Full Analysis Set which was used for the primary and secondary analyses according to intention-to-treat principles. One participant excluded due to missing baseline data at trial period III entry, thus no data could be carried forward for this patient. Missing values imputed by Last Observation Carried Forward.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" spread="1.0037"/>
                    <measurement group_id="O2" value="0.990" spread="1.0034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance (ANCOVA) model was used including treatment group, stratum and pooled centre as fixed effects and log (BMD at Baseline III (month 24)) as a covariate (log-normally distributed data assumed). Least square mean change from baseline III (month 24), 95% confidence interval and p-value for the treatment effect (PTH (1-84) vs. Risedronate) was calculated. Superiority was claimed if lower limit of the interval was above 1. Results were back-transformed from the log scale.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>No multiplicity correction of the significance level was performed as only one primary endpoint was planned.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Estimation allowing for unequal variance in the two treatment groups and robust estimates for the standard errors were obtained.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.003</ci_lower_limit>
            <ci_upper_limit>1.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over three years of the trial duration.</time_frame>
      <desc>The safety analysis set (SAF) was defined as all subjects enrolled in Trial Period I who received at least one dose of the IMP.
At each contact between the site and the subject (visit or phone) the subject was asked if she has experienced any health problems since the last contact.</desc>
      <group_list>
        <group group_id="E1">
          <title>PTH (1-84)</title>
          <description>Trial Period I SAEs and Trial Period III SAEs for subjects receiving PTH (1-84)</description>
        </group>
        <group group_id="E2">
          <title>Risedronate</title>
          <description>Trial Period II SAEs and Trial Period III SAEs for subjects receiving risedronate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Impacted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Essential thrombocythaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="365" subjects_at_risk="405"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="123" subjects_affected="98" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="405"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="105" subjects_affected="87" subjects_at_risk="405"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="405"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="405"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" events="150" subjects_affected="121" subjects_at_risk="405"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After publication of the results or 24 months after Clinical Trial Report has been finalised, whichever comes first, Nycomed acknowledge the Investigator's rights to publish results from this trial. Any such scientific paper, presentation, communication, or other information concerning the investigation described in this protocol, must be submitted to Nycomed prior to submission for publication/presentation for review. Review comments will be given within a month from receipt of the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Operations</name_or_title>
      <organization>Nycomed</organization>
      <phone>+45 4677 1111</phone>
      <email>clinicaltrials@nycomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

